CohBar (COB.U:CA) Using Mitochondria to find a Treatment for Alzheimer's

Spotlight Companies  |

Mitochondrial-Derived Peptides. Science is truly an amazing thing. In case you have forgotten from middle school science class, mitochondria are called the powerhouses of the cell, they are components within the cell that produce energy and communicate with other parts of the body. Well, the scientists and researchers at CohBar Inc. (COB.U:CA) are using mitochondrial genomes to find therapies and cures for unmet medical needs.

Last week, CohBar announced that researchers at the University of Southern California, working alongside with investigators at the Institute for Aging and Research at the Albert Institute College of Medicine of Yeshiva University (Einstein), have discovered a new family of six peptide hormones that will regulate metabolism and cell viability. The preclinical study will be published in the April 2016 issue of Aging under the title, “Naturally Occurring Mitochondrial-derived Peptides are Age-dependent Regulators of Apoptosis, Insulin Sensitivity, and Inflammatory Markers.” CohBar has the exclusive license to develop these metabolism-regulating peptides into therapeutics.

These peptides are technically called small humanin-like peptides (SHLPs) could be used to treat Alzheimer's and even diabetes, diseases associated with aging. These preclinical findings of course are quite exciting and proof that mitochondria-derived peptides deserve further testing and research. Pinchas Cohen, the Founder and Director of CohBar released this quote in a press release:

“Together with the previously described mitochondrial-derived peptides humanin and MOTS-c, the SHLP family expands our understanding of the role that these peptides play in intracellular signaling throughout the body to regulate both metabolism and cell survival…These findings further illustrate the enormous potential that mitochondria-based therapeutics could have on treating age-associated diseases like Alzheimer’s and cancer.”

Findings like this are motivation for CohBar to push the research forward. CEO of CohBar Simon Allen restated this fact in the press release: “The pre-clinical evidence continues to confirm that these peptides represent a new class of naturally occurring metabolic regulators…They form the foundation of our pipeline of first-in-class treatments for age-related diseases and we are committed to rapidly advancing them though pre-clinical and clinical activities as we move forward.”

In the interest of full disclosure, we call the reader's attention to the fact that, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Last Price Change % Change